Interpreting the results of cost-effectiveness studies.
作者： David J. Cohen , Matthew R. Reynolds
DOI: 10.1016/J.JACC.2008.09.018
关键词: Cost effectiveness 、 Health care 、 Time horizon 、 Strengths and weaknesses 、 Quality of life (healthcare) 、 Resource allocation 、 Management science 、 Medicine 、 Medical literature 、 Cost–benefit analysis
摘要: In developed nations, health care spending is an increasingly important economic and political issue. The discipline of cost-effectiveness (CE) analysis has developed over several …
core.ac.uk
onlinejacc.org
elsevier.com参考文章(44)
A. Williams, EuroQol : a new facility for the measurement of health-related quality of life Health Policy. ,vol. 16, pp. 199- 208 ,(1990)
Ameet Bakhai, Gregg W Stone, Elizabeth Mahoney, Tara A Lavelle, Chunxue Shi, Ronna H Berezin, Betsy J Lahue, Mary Ann Clark, Michael J Lacey, Mary E Russell, Stephen G Ellis, James B Hermiller, David A Cox, David J Cohen, TAXUS-IV Investigators, Cost Effectiveness of Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization Results From the TAXUS-IV Trial Journal of the American College of Cardiology. ,vol. 48, pp. 253- 261 ,(2006) , 10.1016/J.JACC.2006.02.063
Pallav Garg, David J. Cohen, Thomas Gaziano, Laura Mauri, Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents Results of a Decision Analytic Model Journal of the American College of Cardiology. ,vol. 51, pp. 1844- 1853 ,(2008) , 10.1016/J.JACC.2008.01.042
Peter J Neumann, Gillian D Sanders, Louise B Russell, Joanna E Siegel, Theodore G Ganiats, None, Cost-effectiveness in health and medicine Oxford University Press. ,(1996)
George W. Torrance, Measurement of health state utilities for economic appraisal. Journal of Health Economics. ,vol. 5, pp. 1- 30 ,(1986) , 10.1016/0167-6296(86)90020-2
Jack Zwanziger, W. Jackson Hall, Andrew W. Dick, Hongwei Zhao, Alvin I. Mushlin, Rebecca Marron Hahn, Hongkun Wang, Mark L. Andrews, Cathleen Mooney, Hongyue Wang, Arthur J. Moss, The Cost Effectiveness of Implantable Cardioverter-Defibrillators: Results From the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II Journal of the American College of Cardiology. ,vol. 47, pp. 2310- 2318 ,(2006) , 10.1016/J.JACC.2006.03.032
David M. Cutler, Allison B. Rosen, Sandeep Vijan, The Value of Medical Spending in the United States, 1960–2000 The New England Journal of Medicine. ,vol. 355, pp. 920- 927 ,(2006) , 10.1056/NEJMSA054744
David H. Mark, Visualizing Cost-effectiveness Analysis JAMA. ,vol. 287, pp. 2428- 2429 ,(2002) , 10.1001/JAMA.287.18.2428
Gillian D. Sanders, Mark A. Hlatky, Nathan R. Every, Kathryn M. McDonald, Paul A. Heidenreich, Lori S. Parsons, Douglas K. Owens, Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Annals of Internal Medicine. ,vol. 135, pp. 870- 883 ,(2001) , 10.7326/0003-4819-135-10-200111200-00007
Y Chen, P Jobanputra, P Barton, S Bryan, A Fry-Smith, G Harris, R Taylor, Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Health Technology Assessment. ,vol. 12, pp. 1- ,(2008) , 10.3310/HTA12110